User contributions
Jump to navigation
Jump to search
- 10:01, 31 March 2024 diff hist +29 m Mitapivat (Pyrukynd) →Pyruvate kinase deficiency
- 09:58, 31 March 2024 diff hist +32 m Mitapivat (Pyrukynd) →History of changes in FDA indication
- 01:19, 31 March 2024 diff hist 0 m Myelofibrosis →Lenalidomide monotherapy {{#subobject:1 |Regimen=1}}
- 00:24, 31 March 2024 diff hist 0 m Osteosarcoma - historical →MAPifn [COG AOST0331]
- 00:15, 31 March 2024 diff hist +282 m Esophageal squamous cell carcinoma →Fluorouracil, Mitomycin, RT {{#subobject:52e7mi|Regimen=1}}
- 00:10, 31 March 2024 diff hist +500 m Colorectal cancer →Intrahepatic floxuridine & IV 5-FU {{#subobject:8fjn3c|Regimen=1}}
- 22:07, 30 March 2024 diff hist +1,206 m Mantle cell lymphoma →Lenalidomide & Rituximab (R2) {{#subobject:3d8123|Regimen=1}}
- 21:43, 30 March 2024 diff hist +1,108 m B-cell acute lymphoblastic leukemia →Cyclophosphamide & TBI, then allo HSCT {{#subobject:a9e6e8|Regimen=1}}
- 20:11, 30 March 2024 diff hist +984 m Allogeneic HSCT →Busulfan & Cyclophosphamide {{#subobject:83e07a|Regimen=1}}
- 20:11, 30 March 2024 diff hist +1,124 m Myelodysplastic syndrome →Busulfan & Cyclophosphamide, then allo HSCT {{#subobject:83e07a|Regimen=1}}
- 20:09, 30 March 2024 diff hist +1,123 m Acute myeloid leukemia →Busulfan & Cyclophosphamide, then allo HSCT {{#subobject:83e07a|Regimen=1}}
- 20:07, 30 March 2024 diff hist +78 m Acute myeloid leukemia →References
- 20:05, 30 March 2024 diff hist +157 m Allogeneic HSCT →Fludarabine & TBI for haploidentical transplant
- 18:06, 30 March 2024 diff hist +776 m Myelodysplastic syndrome →References
- 18:05, 30 March 2024 diff hist +776 m Acute myeloid leukemia →References
- 18:01, 30 March 2024 diff hist +1,818 m Acute myeloid leukemia →Busulfan & Fludarabine, then allo HSCT {{#subobject:3fe0f0|Regimen=1}}
- 17:58, 30 March 2024 diff hist +2,160 Myelodysplastic syndrome →Busulfan & Cyclophosphamide, then allo HSCT {{#subobject:83e07a|Regimen=1}}
- 17:46, 30 March 2024 diff hist +31 m Myelodysplastic syndrome →Prognosis
- 17:45, 30 March 2024 diff hist +441 m Blastic plasmacytoid dendritic cell neoplasm
- 17:45, 30 March 2024 diff hist -207 m Acute myeloid leukemia →NCCN
- 17:44, 30 March 2024 diff hist +31 m Acute promyelocytic leukemia →References
- 17:43, 30 March 2024 diff hist -13 m Category:Myeloproliferative neoplasms
- 17:43, 30 March 2024 diff hist +43 N Category:Myeloid neoplasms Created page with "Category:Malignant hematologic neoplasm" current
- 17:42, 30 March 2024 diff hist +31 m Acute myeloid leukemia →Additional information
- 17:04, 30 March 2024 diff hist +1,883 m B-cell acute lymphoblastic leukemia, pediatric →Etoposide & TBI, then allo HSCT {{#subobject:b389e1|Regimen=1}}
- 01:40, 30 March 2024 diff hist +1 m Bicalutamide (Casodex) →History of changes in EMA indication current
- 01:39, 30 March 2024 diff hist +1 m BCG vaccine →History of changes in EMA indication current
- 00:34, 30 March 2024 diff hist -1 m High-grade glioma, pediatric →Temozolomide & RT {{#subobject:5fe805|Regimen=1}}
- 00:28, 30 March 2024 diff hist -1 m Anaplastic glioma →RT, then Temozolomide {{#subobject:48949a|Regimen=1}}
- 11:13, 29 March 2024 diff hist +65 m Osteosarcoma →IE {{#subobject:29f233|Regimen=1}}
- 11:07, 29 March 2024 diff hist -12 m Cervical cancer →Hydroxyurea & RT {{#subobject:b93f37|Regimen=1}}
- 11:03, 29 March 2024 diff hist +66 m Follicular lymphoma →Regimen variant #2, 3 cycles with prednisone 100 mg/m2 {{#subobject:aae4db|Variant=1}}
- 11:02, 29 March 2024 diff hist +66 m Follicular lymphoma →Regimen variant #3 {{#subobject:2a6690|Variant=1}}
- 11:02, 29 March 2024 diff hist +72 m Follicular lymphoma →Regimen variant #2 {{#subobject:d69b11|Variant=1}}
- 11:01, 29 March 2024 diff hist -26 m Pancreatic cancer →Gemcitabine & RT {{#subobject:a6e6fc|Regimen=1}}
- 10:54, 29 March 2024 diff hist -32 m Rectal cancer →Regimen variant #3, CI 5-FU, then CI 5-FU & RT, then CI 5-FU {{#subobject:da8c0d|Variant=1}}
- 10:47, 29 March 2024 diff hist +11 m Multiple myeloma - historical →DEX-IFN {{#subobject:144646|Regimen=1}}
- 01:24, 29 March 2024 diff hist +765 m Allogeneic HSCT
- 01:11, 29 March 2024 diff hist +115 m Mantle cell lymphoma →Regimen variant #2, alternating {{#subobject:baugja|Variant=1}}
- 16:00, 28 March 2024 diff hist +312 m Waldenström macroglobulinemia →BDR {{#subobject:2529c7|Regimen=1}}
- 15:36, 28 March 2024 diff hist -1 m Waldenström macroglobulinemia
- 12:37, 28 March 2024 diff hist +93 m Multiple myeloma, relapsed-refractory →Daratumumab monotherapy {{#subobject:d45aea|Regimen=1}}
- 12:33, 28 March 2024 diff hist +258 m Light-chain (AL) amyloidosis →Daratumumab monotherapy {{#subobject:866e6e|Regimen=1}}
- 11:04, 28 March 2024 diff hist -7 m Breast cancer, ER and HER2 co-expressing →Endocrine therapy
- 19:58, 27 March 2024 diff hist -14 m Hepatocellular carcinoma →References
- 19:56, 27 March 2024 diff hist +24 m Multiple myeloma, induction current
- 11:29, 27 March 2024 diff hist -1 m Peripheral T-cell lymphoma →Supportive therapy
- 11:23, 26 March 2024 diff hist +2,061 Esophageal squamous cell carcinoma →Cisplatin & Fluorouracil (CF) & Sintilimab {{#subobject:717obb|Regimen=1}}
- 11:10, 26 March 2024 diff hist +1,879 m Esophageal squamous cell carcinoma →Cisplatin & Fluorouracil (CF) {{#subobject:4d9936|Regimen=1}}
- 01:35, 26 March 2024 diff hist +5 m Acute promyelocytic leukemia →Targeted therapy
- 00:34, 26 March 2024 diff hist +1,484 m Breast cancer - historical →Melphalan monotherapy {{#subobject:b913c5|Regimen=1}}
- 00:31, 26 March 2024 diff hist -19 m Breast cancer →Metastatic disease, subsequent lines of chemotherapy
- 00:26, 26 March 2024 diff hist +1,413 m Breast cancer - historical →Melphalan monotherapy {{#subobject:b062c5|Regimen=1}}
- 00:22, 26 March 2024 diff hist -395 m Breast cancer - historical →CFP {{#subobject:b514cd|Regimen=1}}
- 00:20, 26 March 2024 diff hist +1,500 m Breast cancer - historical →Melphalan monotherapy {{#subobject:b062c5|Regimen=1}}
- 01:12, 25 March 2024 diff hist +213 m Glioblastoma →Cyclophosphamide monotherapy {{#subobject:1724a|Regimen=1}}
- 01:07, 25 March 2024 diff hist +43 m Gestational trophoblastic neoplasia →Low-risk disease, all lines of therapy
- 23:39, 24 March 2024 diff hist -192 m Breast cancer, ER and HER2 co-expressing
- 20:00, 24 March 2024 diff hist -29 m Diffuse large B-cell lymphoma
- 19:50, 24 March 2024 diff hist +12 m Melanoma, BRAF-mutated
- 18:08, 24 March 2024 diff hist +155 m Colorectal cancer, RAS wild-type →Subsequent treatment
- 18:06, 24 March 2024 diff hist +22 m Colorectal cancer, RAS wild-type
- 18:03, 24 March 2024 diff hist +619 m ASCO guidelines →Infectious diseases
- 17:59, 24 March 2024 diff hist +125 m Classical Hodgkin lymphoma - historical
- 17:48, 24 March 2024 diff hist +855 m Multiple myeloma, consolidation and maintenance
- 17:06, 24 March 2024 diff hist -3 m Transformed lymphoma
- 17:04, 24 March 2024 diff hist -2 m Thymoma
- 17:03, 24 March 2024 diff hist +38 m Stem cell mobilization regimens
- 17:00, 24 March 2024 diff hist +24 m Small cell lung cancer
- 16:56, 24 March 2024 diff hist -13 m Stem cell mobilization regimens
- 12:03, 24 March 2024 diff hist +1 m Urothelial carcinoma →Regimen variant #2, AUC 4.5/1000, indefinite {{#subobject:5f0in7|Variant=1}}
- 12:02, 24 March 2024 diff hist -51 m Urothelial carcinoma →Chemotherapy
- 11:42, 24 March 2024 diff hist +2 m Non-small cell lung cancer →References
- 11:42, 24 March 2024 diff hist +2,311 m Non-small cell lung cancer →Carboplatin & Paclitaxel (CP) {{#subobject:81d5a7|Regimen=1}}
- 11:39, 24 March 2024 diff hist +159 m Non-small cell lung cancer →Carboplatin & Paclitaxel (CP) & RT {{#subobject:899399|Regimen=1}}
- 11:37, 24 March 2024 diff hist +2,765 m Non-small cell lung cancer - historical →MVP & RT {{#subobject:10d15d|Regimen=1}}
- 11:30, 24 March 2024 diff hist +114 m Non-small cell lung cancer →Carboplatin & Paclitaxel (CP) & RT {{#subobject:899399|Regimen=1}}
- 11:24, 24 March 2024 diff hist +1,644 Neuroendocrine tumor →Everolimus monotherapy {{#subobject:99989f|Regimen=1}}
- 11:23, 24 March 2024 diff hist +54 m Neuroendocrine tumor →Fluorouracil & Streptozocin {{#subobject:bd8397|Regimen=1}}
- 11:21, 24 March 2024 diff hist -4 m Neuroendocrine tumor →Fluorouracil & Streptozocin {{#subobject:bd8397|Regimen=1}}
- 02:30, 24 March 2024 diff hist +4 m Kaposi sarcoma →Pegylated liposomal doxorubicin monotherapy {{#subobject:a880c2|Regimen=1}}
- 02:29, 24 March 2024 diff hist +1,538 Kaposi sarcoma →Bevacizumab monotherapy {{#subobject:25316e|Regimen=1}}
- 02:21, 24 March 2024 diff hist -38 m Non-small cell lung cancer
- 02:21, 24 March 2024 diff hist -18 m Malignant pleural mesothelioma
- 02:17, 24 March 2024 diff hist +150 m Breast cancer →Regimen variant #2 {{#subobject:bf8gub|Variant=1}}
- 02:10, 24 March 2024 diff hist +1,849 Breast cancer, ER-positive →Neoadjuvant endocrine therapy, postmenopausal
- 00:24, 24 March 2024 diff hist -13 m Non-small cell lung cancer
- 00:23, 24 March 2024 diff hist -13 m Head and neck cancer
- 00:23, 24 March 2024 diff hist -28 m Non-small cell lung cancer - null regimens →Observation
- 00:22, 24 March 2024 diff hist -28 m Non-small cell lung cancer - null regimens →Observation
- 00:22, 24 March 2024 diff hist -12 m Non-small cell lung cancer, nonsquamous →Tegafur & uracil monotherapy {{#subobject:ac88ea|Regimen=1}}
- 13:29, 23 March 2024 diff hist +1 m Medulloblastoma - historical →VCP [CCG-921] {{#subobject:3dy31n|Regimen=1}}
- 13:27, 23 March 2024 diff hist -11 m High-grade glioma, pediatric →Adjuvant therapy
- 13:13, 23 March 2024 diff hist 0 m Diffuse large B-cell lymphoma - historical →MINE {{#subobject:aff118|Regimen=1}}
- 13:12, 23 March 2024 diff hist -28 m Diffuse large B-cell lymphoma - historical →Relapsed or refractory, salvage therapy
- 12:42, 23 March 2024 diff hist +703 m B-cell acute lymphoblastic leukemia, pediatric, Ph-positive →Daunorubicin, Pegaspargase, Vincristine, Prednisone, Imatinib {{#subobject:d3yhc7|Regimen=1}}
- 12:37, 23 March 2024 diff hist +703 m B-cell acute lymphoblastic leukemia, pediatric, Ph-positive →Daunorubicin, Pegaspargase, Vincristine, Prednisone, Dasatinib {{#subobject:d3ob07|Regimen=1}}
- 12:25, 23 March 2024 diff hist +2,810 m B-cell acute lymphoblastic leukemia →Relapsed or refractory
- 12:25, 23 March 2024 diff hist -2,834 m B-cell acute lymphoblastic leukemia →Cytarabine & Mitoxantrone (MC) {{#subobject:6237f0|Regimen=1}}
- 12:25, 23 March 2024 diff hist -30 m B-cell acute lymphoblastic leukemia →Inotuzumab ozogamicin monotherapy {{#subobject:d90806|Regimen=1}}
- 12:19, 23 March 2024 diff hist +8 m Acute myeloid leukemia, NPM1-mutated →Cytarabine & Etoposide {{#subobject:e8gacb|Regimen=1}}
- 12:13, 23 March 2024 diff hist -27 m Diffuse large B-cell lymphoma
- 11:28, 23 March 2024 diff hist +34 m Mantle cell lymphoma →maxi-R-CHOP/R-HiDAC {{#subobject:360f9d|Regimen=1}}
- 11:17, 23 March 2024 diff hist 0 m Small cell lung cancer
- 11:16, 23 March 2024 diff hist +5,168 m Small cell lung cancer - historical →CDE {{#subobject:344f89|Regimen=1}}
- 11:11, 23 March 2024 diff hist -5,212 m Small cell lung cancer - historical →ACE {{#subobject:9fbf31|Regimen=1}}
- 11:02, 23 March 2024 diff hist +12 m Mantle cell lymphoma
- 11:01, 23 March 2024 diff hist +2 m Mantle cell lymphoma →R-MACLO/R-IVAM {{#subobject:51391f|Regimen=1}}
- 11:01, 23 March 2024 diff hist +8,730 m Mantle cell lymphoma →R-DHAC {{#subobject:ed2a61|Regimen=1}}
- 10:59, 23 March 2024 diff hist -8,411 m Mantle cell lymphoma →R-MACLO/R-IVAM {{#subobject:51391f|Regimen=1}}
- 10:52, 23 March 2024 diff hist +3 m Non-small cell lung cancer →Subsequent treatment
- 10:47, 23 March 2024 diff hist +91 m Non-small cell lung cancer - historical →VIP (Vinblastine) {{#subobject:e6f7b9|Regimen=1}}
- 10:43, 23 March 2024 diff hist +21 m Endometrial cancer
- 10:42, 23 March 2024 diff hist +1,590 m Endometrial cancer →Cisplatin & Paclitaxel {{#subobject:89fd88|Regimen=1}}
- 10:40, 23 March 2024 diff hist -1,393 m Endometrial cancer →CIM {{#subobject:ac4ecc|Regimen=1}}
- 10:39, 23 March 2024 diff hist +42 m Endometrial cancer →Adjuvant therapy
- 02:13, 23 March 2024 diff hist +1 m Multiple myeloma, consolidation and maintenance →Preceding treatment
- 02:12, 23 March 2024 diff hist +236 m Multiple myeloma - historical
- 02:09, 23 March 2024 diff hist +12 m Multiple myeloma, induction →Synopsis
- 02:02, 23 March 2024 diff hist +136 m Thymoma
- 01:57, 23 March 2024 diff hist +2,443 m Non-small cell lung cancer - historical →Cisplatin monotherapy {{#subobject:a0eb49|Regimen=1}}
- 01:56, 23 March 2024 diff hist -2,348 m Non-small cell lung cancer - historical →CAP (Platinol) {{#subobject:379e5f|Regimen=1}}
- 01:56, 23 March 2024 diff hist -52 m Ovarian cancer
- 01:55, 23 March 2024 diff hist +135 m Ovarian cancer - historical
- 01:52, 23 March 2024 diff hist -2,238 m Urothelial carcinoma →Locally advanced or metastatic disease, first-line, platinum-eligible
- 01:51, 23 March 2024 diff hist +2,272 m Urothelial carcinoma - historical →Cisplatin monotherapy {{#subobject:1af7a9|Regimen=1}}
- 01:07, 23 March 2024 diff hist +31 m Non-small cell lung cancer
- 01:07, 23 March 2024 diff hist +2,271 m Non-small cell lung cancer →Carboplatin & Gemcitabine (GCb) {{#subobject:8669e|Regimen=1}}
- 01:06, 23 March 2024 diff hist -2,243 m Non-small cell lung cancer →PCG (Carboplatin) {{#subobject:45t1c7|Regimen=1}}
- 00:58, 23 March 2024 diff hist +23 m Acute myeloid leukemia, pediatric
- 00:51, 23 March 2024 diff hist -64 m Classical Hodgkin lymphoma →Consolidation after salvage therapy
- 00:49, 23 March 2024 diff hist -50 m Allogeneic HSCT →Reduced-intensity conditioning (RIC), all lines of therapy
- 00:39, 23 March 2024 diff hist +28 m Classical Hodgkin lymphoma
- 00:37, 23 March 2024 diff hist +24 m Classical Hodgkin lymphoma
- 00:28, 23 March 2024 diff hist +123 m Acute myeloid leukemia
- 00:05, 23 March 2024 diff hist +65 m Mantle cell lymphoma - historical
- 00:03, 23 March 2024 diff hist +15 m Light-chain (AL) amyloidosis - null regimens →Subsequent treatment current
- 00:00, 23 March 2024 diff hist +83 m Light-chain (AL) amyloidosis
- 23:55, 22 March 2024 diff hist +96 m Colorectal cancer, RAS wild-type
- 20:27, 22 March 2024 diff hist +1,613 B-cell acute lymphoblastic leukemia, Ph-positive →Upfront induction therapy
- 20:20, 22 March 2024 diff hist +256 m Ponatinib (Iclusig) current
- 18:29, 22 March 2024 diff hist +307 m Mirvetuximab soravtansine (Elahere) current
- 18:29, 22 March 2024 diff hist +4 m Ovarian cancer →Regimen {{#subobject:1ugjzgu|Variant=1}}
- 18:20, 22 March 2024 diff hist -16 m Enzalutamide (Xtandi) →History of changes in FDA indication current
- 17:05, 22 March 2024 diff hist +208 m Adrenocortical carcinoma
- 17:03, 22 March 2024 diff hist -12 m Acute myeloid leukemia
- 16:59, 22 March 2024 diff hist -1 m Acquired thrombotic thrombocytopenic purpura
- 16:27, 22 March 2024 diff hist +45 m Diffuse large B-cell lymphoma →R-DHAOx {{#subobject:0d0c67|Regimen=1}}
- 16:03, 22 March 2024 diff hist +1 m B-cell acute lymphoblastic leukemia, pediatric →Interim Maintenance, I with HD MTX {{#subobject:98346f|Variant=1}}
- 12:17, 22 March 2024 diff hist +103 m Diffuse large B-cell lymphoma - historical →P/DOCE {{#subobject:375d4a|Regimen=1}}
- 12:09, 22 March 2024 diff hist +19 m Diffuse large B-cell lymphoma - historical
- 12:05, 22 March 2024 diff hist +46 m Follicular lymphoma →Regimen variant #2, len dose escalation 15 -> 25 x 12 {{#subobject:20e899|Variant=1}}
- 12:01, 22 March 2024 diff hist -8 m Follicular lymphoma →Ibritumomab tiuxetan protocol {{#subobject:37d27b|Regimen=1}}
- 11:33, 22 March 2024 diff hist 0 m Bladder cancer →Gemcitabine & RT {{#subobject:91c0ea|Regimen=1}}
- 11:29, 22 March 2024 diff hist -12 m Anal cancer
- 11:12, 22 March 2024 diff hist +2 m Acute myeloid leukemia, pediatric →Intensification, part II
- 11:06, 22 March 2024 diff hist 0 m Esophageal squamous cell carcinoma →Cisplatin, Vinorelbine, RT {{#subobject:d72171|Regimen=1}}
- 11:05, 22 March 2024 diff hist 0 m Non-small cell lung cancer →Cisplatin, Pemetrexed, RT {{#subobject:74ugg8|Regimen=1}}
- 11:03, 22 March 2024 diff hist -175 m Bladder cancer
- 10:57, 22 March 2024 diff hist -2 m Non-small cell lung cancer →Cisplatin, Etoposide, RT {{#subobject:743aa8|Regimen=1}}
- 10:56, 22 March 2024 diff hist +3 m Non-small cell lung cancer →Cisplatin, Etoposide, RT {{#subobject:743aa8|Regimen=1}}
- 02:07, 22 March 2024 diff hist +3 m Chronic lymphocytic leukemia
- 02:02, 22 March 2024 diff hist +6 m Non-small cell lung cancer
- 02:01, 22 March 2024 diff hist +3 m Head and neck cancer →Regimen variant #4, 100 mg/m2 x 3, 6000 cGy {{#subobject:21d2ff|Variant=1}}
- 01:59, 22 March 2024 diff hist +13 m Endometrial cancer →Cisplatin & RT {{#subobject:4d8gh0|Regimen=1}}
- 01:55, 22 March 2024 diff hist -3 m Head and neck cancer →Carboplatin, Fluorouracil, Cetuximab, RT {{#subobject:db85fc|Regimen=1}}
- 01:53, 22 March 2024 diff hist +32 m Head and neck cancer - historical
- 01:50, 22 March 2024 diff hist +21 m Esophageal cancer
- 01:45, 22 March 2024 diff hist +1 m Esophageal cancer →Capecitabine, Cisplatin, RT {{#subobject:dfe688|Regimen=1}}
- 01:43, 22 March 2024 diff hist +13 m Glioblastoma →Bevacizumab & RT {{#subobject:ee9fbd|Regimen=1}}
- 01:10, 22 March 2024 diff hist +2 m Chronic lymphocytic leukemia →Regimen variant #2, 0.7 mg/m2 {{#subobject:57becf|Variant=1}}
- 18:00, 20 March 2024 diff hist -33 m Waldenström macroglobulinemia →IWWM
- 17:59, 20 March 2024 diff hist -75 m Waldenström macroglobulinemia →ESMO
- 00:19, 19 March 2024 diff hist +4 m Study Groups →Main table
- 20:48, 17 March 2024 diff hist +14 m Non-small cell lung cancer - historical →VIP {{#subobject:e6f7b9|Regimen=1}}
- 20:45, 17 March 2024 diff hist 0 m Gastric cancer →UFT monotherapy {{#subobject:ecufef|Regimen=1}}
- 20:16, 17 March 2024 diff hist +10 m Myelofibrosis →Lenalidomide monotherapy {{#subobject:1 |Regimen=1}}
- 18:30, 17 March 2024 diff hist +62 m Allogeneic HSCT
- 18:29, 17 March 2024 diff hist -3 m Renal cell carcinoma - historical
- 18:29, 17 March 2024 diff hist -3 m Chronic lymphocytic leukemia
- 17:43, 17 March 2024 diff hist +45 m Clear cell renal cell carcinoma →Belzutifan monotherapy {{#subobject:anc684|Regimen=1}}
- 00:53, 15 March 2024 diff hist -1 m Breast cancer, HER2-positive →Targeted therapy
- 21:01, 14 March 2024 diff hist +13 m Melanoma, BRAF-mutated →Immunotherapy
- 02:04, 14 March 2024 diff hist -17 m Mantle cell lymphoma →R-Hyper-CVAD/R-MA {{#subobject:a76238|Regimen=1}}
- 01:38, 14 March 2024 diff hist +3,382 m Gastric cancer →Docetaxel & S-1 {{#subobject:a22c2a|Regimen=1}}
- 01:11, 14 March 2024 diff hist +2 m Breast cancer - historical →Chemotherapy, CMF portion (cycles 2, 4, 6, 8, 10, 12
- 00:31, 13 March 2024 diff hist +146 m Small cell lung cancer
- 20:07, 12 March 2024 diff hist -1 m Chronic lymphocytic leukemia →Targeted therapy
- 13:53, 12 March 2024 diff hist +131 m Breast cancer, HER2-positive →THP (Docetaxel) {{#subobject:24b376|Regimen=1}}
- 13:51, 12 March 2024 diff hist +1,359 m Breast cancer, HER2-positive →References
- 13:50, 12 March 2024 diff hist +780 m Breast cancer, HER2-positive
- 13:09, 12 March 2024 diff hist +39 m Mantle cell lymphoma →R-Hyper-CVAD/R-MA {{#subobject:a76238|Regimen=1}}
- 13:06, 12 March 2024 diff hist +2 m Multiple myeloma, induction →Glucocorticoid therapy
- 13:05, 12 March 2024 diff hist 0 m Breast cancer, HER2-positive
- 13:04, 12 March 2024 diff hist +1 m Classical Hodgkin lymphoma →Chemotherapy
- 12:43, 12 March 2024 diff hist -10 m Chronic lymphocytic leukemia →Targeted therapy
- 16:52, 11 March 2024 diff hist +3,387 m Urothelial carcinoma
- 01:00, 11 March 2024 diff hist -552 m Light-chain (AL) amyloidosis →Bortezomib & Melphalan, then auto HSCT {{#subobject:5426f4|Regimen=1}}
- 00:59, 10 March 2024 diff hist +17 m Breast cancer, HER2-positive →Targeted therapy, TL portion (cycles 5 to 8)
- 03:04, 9 March 2024 diff hist -329 m CNS lymphoma →Bu/TT/Cy, then auto HSCT {{#subobject:e04a91|Regimen=1}}
- 03:04, 9 March 2024 diff hist -232 m CNS lymphoma →Bu/TT, then auto HSCT {{#subobject:e04a91|Regimen=1}}
- 03:03, 9 March 2024 diff hist +1 m Autologous HSCT →Bu/TT/Cy {{#subobject:e04a91|Regimen=1}}
- 03:02, 9 March 2024 diff hist -947 m CNS lymphoma →BEAM, then auto HSCT {{#subobject:c9216e|Regimen=1}}
- 03:00, 9 March 2024 diff hist -757 m CNS lymphoma →BCNU/TT, then auto HSCT {{#subobject:a7b7ae|Regimen=1}}
- 01:24, 9 March 2024 diff hist +32 m Breast cancer, ER-positive
- 22:38, 8 March 2024 diff hist +53 m Inotuzumab ozogamicin (Besponsa) current
- 22:26, 8 March 2024 diff hist +123 m Inotuzumab ozogamicin (Besponsa) →History of changes in FDA indication
- 20:05, 8 March 2024 diff hist 0 m Urothelial carcinoma
- 20:04, 8 March 2024 diff hist 0 m Soft tissue sarcoma
- 20:03, 8 March 2024 diff hist 0 m Small cell lung cancer
- 20:03, 8 March 2024 diff hist 0 m Small cell lung cancer - null regimens
- 20:03, 8 March 2024 diff hist 0 m Renal cell carcinoma
- 20:02, 8 March 2024 diff hist 0 m Renal cell carcinoma - null regimens current
- 20:01, 8 March 2024 diff hist 0 m Rectal cancer - null regimens
- 20:01, 8 March 2024 diff hist 0 m Non-small cell lung cancer - historical
- 20:00, 8 March 2024 diff hist 0 m Non-small cell lung cancer - null regimens
- 20:00, 8 March 2024 diff hist 0 m Neuroendocrine tumor
- 19:59, 8 March 2024 diff hist +19 m Hepatocellular carcinoma
- 19:58, 8 March 2024 diff hist 0 m Hepatocellular carcinoma - null regimens current
- 19:57, 8 March 2024 diff hist 0 m Diffuse large B-cell lymphoma
- 19:57, 8 March 2024 diff hist 0 m Diffuse large B-cell lymphoma - null regimens
- 19:56, 8 March 2024 diff hist 0 m Acute myeloid leukemia
- 19:55, 8 March 2024 diff hist 0 m Acute myeloid leukemia - null regimens
- 19:55, 8 March 2024 diff hist 0 m Acute lymphoblastic leukemia, infant
- 19:54, 8 March 2024 diff hist 0 m Cervical cancer
- 19:54, 8 March 2024 diff hist 0 m Cervical cancer - historical
- 19:53, 8 March 2024 diff hist 0 m Breast cancer, PIK3CA-mutated
- 19:53, 8 March 2024 diff hist 0 m Breast cancer, HER2-positive - null regimens current
- 19:52, 8 March 2024 diff hist 0 m Breast cancer, ER-positive
- 19:51, 8 March 2024 diff hist 0 m Breast cancer, ER-positive - historical
- 19:50, 8 March 2024 diff hist 0 m Breast cancer - historical
- 19:50, 8 March 2024 diff hist +19 m Breast cancer
- 19:49, 8 March 2024 diff hist 0 m Breast cancer - null regimens
- 19:48, 8 March 2024 diff hist 0 m Bladder cancer
- 19:48, 8 March 2024 diff hist 0 m Bladder cancer - null regimens current
- 13:22, 8 March 2024 diff hist +16 m Breast cancer, HER2-positive - historical
- 01:27, 8 March 2024 diff hist 0 m Prostate cancer - historical
- 01:27, 8 March 2024 diff hist 0 m Prostate cancer
- 01:26, 8 March 2024 diff hist 0 m Prostate cancer - null regimens
- 01:25, 8 March 2024 diff hist 0 m Peripheral T-cell lymphoma
- 01:25, 8 March 2024 diff hist 0 m Peripheral T-cell lymphoma - historical
- 01:24, 8 March 2024 diff hist 0 m Papillary renal cell carcinoma
- 01:24, 8 March 2024 diff hist 0 m Pancreatic cancer, BRCA-mutated
- 01:23, 8 March 2024 diff hist 0 m Pancreatic cancer
- 01:22, 8 March 2024 diff hist 0 m Pancreatic cancer - null regimens current
- 01:22, 8 March 2024 diff hist 0 m Ovarian cancer - historical
- 01:22, 8 March 2024 diff hist 0 m Ovarian cancer
- 01:21, 8 March 2024 diff hist 0 m Ovarian cancer - null regimens current
- 01:20, 8 March 2024 diff hist 0 m Non-small cell lung cancer, squamous
- 01:19, 8 March 2024 diff hist 0 m Non-small cell lung cancer, nonsquamous
- 00:13, 8 March 2024 diff hist +3 m Urothelial carcinoma
- 00:13, 8 March 2024 diff hist +7 m Nivolumab (Opdivo)
- 00:12, 8 March 2024 diff hist +224 m Nivolumab (Opdivo)
- 00:06, 8 March 2024 diff hist +305 m Zanubrutinib (Brukinsa) current
- 16:01, 7 March 2024 diff hist 0 m Angiosarcoma
- 16:01, 7 March 2024 diff hist 0 m Acute myeloid leukemia, pediatric - historical
- 15:59, 7 March 2024 diff hist 0 m Anaplastic glioma
- 15:29, 7 March 2024 diff hist +24 m Chronic lymphocytic leukemia →Zanubrutinib monotherapy {{#subobject:67ytze|Regimen=1}}
- 11:51, 7 March 2024 diff hist +668 m Hepatocellular carcinoma
- 18:32, 6 March 2024 diff hist 0 m Non-small cell lung cancer, EGFR-mutated
- 18:30, 6 March 2024 diff hist 0 m Myelodysplastic syndrome
- 18:29, 6 March 2024 diff hist 0 m Myelodysplastic syndrome - null regimens current
- 18:29, 6 March 2024 diff hist 0 m Multiple myeloma - historical
- 18:28, 6 March 2024 diff hist +104 m Myelofibrosis
- 13:12, 6 March 2024 diff hist +1,126 m Head and neck cancer →Methotrexate monotherapy {{#subobject:dc3e62|Regimen=1}}
- 12:05, 6 March 2024 diff hist -57 m Melanoma
- 12:03, 6 March 2024 diff hist 0 m Melanoma - null regimens
- 12:02, 6 March 2024 diff hist 0 m Melanoma - historical
- 12:00, 6 March 2024 diff hist 0 m Malignant pleural mesothelioma
- 11:59, 6 March 2024 diff hist 0 m Kaposi sarcoma - null regimens current
- 11:58, 6 March 2024 diff hist +20 m Head and neck cancer
- 11:55, 6 March 2024 diff hist +1,797 m Follicular lymphoma
- 02:05, 6 March 2024 diff hist 0 m Glioblastoma
- 02:04, 6 March 2024 diff hist +19 m Gastric cancer
- 02:02, 6 March 2024 diff hist 0 m Ewing sarcoma
- 02:02, 6 March 2024 diff hist +28 m Esophageal squamous cell carcinoma - null regimens current
- 02:01, 6 March 2024 diff hist 0 m Esophageal adenocarcinoma
- 02:00, 6 March 2024 diff hist 0 m Chronic lymphocytic leukemia
- 01:59, 6 March 2024 diff hist 0 m Chronic myelomonocytic leukemia
- 01:59, 6 March 2024 diff hist 0 m Clear cell renal cell carcinoma
- 01:58, 6 March 2024 diff hist 0 m Colorectal cancer, RAS wild-type
- 01:58, 6 March 2024 diff hist 0 m Colorectal cancer - historical
- 01:57, 6 March 2024 diff hist 0 m Colorectal cancer
- 01:56, 6 March 2024 diff hist 0 m Colorectal cancer - null regimens
- 20:23, 5 March 2024 diff hist -12 m Breast cancer
- 20:21, 5 March 2024 diff hist -4 m HIV-associated lymphoma
- 20:20, 5 March 2024 diff hist -3 m Esophageal squamous cell carcinoma →Chemotherapy
- 20:20, 5 March 2024 diff hist -4 m Esophageal squamous cell carcinoma
- 20:19, 5 March 2024 diff hist -8 m Cholangiocarcinoma
- 20:18, 5 March 2024 diff hist -8 m Gallbladder cancer
- 20:17, 5 March 2024 diff hist -3 m Acute myeloid leukemia →Chemotherapy
- 20:16, 5 March 2024 diff hist -10 m Acute myeloid leukemia, pediatric
- 17:00, 5 March 2024 diff hist -8 m Neuroblastoma
- 16:59, 5 March 2024 diff hist -12 m Large granular lymphocytic leukemia →Immunosuppressive therapy
- 16:58, 5 March 2024 diff hist -3 m Chronic lymphocytic leukemia →Chemotherapy
- 16:57, 5 March 2024 diff hist -4 m Allogeneic HSCT
- 15:57, 5 March 2024 diff hist -6 m Lifileuecel (Contego) →History of changes in FDA indication current
- 15:11, 5 March 2024 diff hist 0 m Non-small cell lung cancer
- 15:09, 5 March 2024 diff hist +683 m Non-small cell lung cancer →Docetaxel monotherapy {{#subobject:ff8fa6|Regimen=1}}
- 19:07, 4 March 2024 diff hist +5 m Neuroblastoma →Isotretinoin & Dinutuximab {{#subobject:d0nx60|Regimen=1}}
- 19:07, 4 March 2024 diff hist +520 m Neuroblastoma →Isotretinoin & Dinutuximab {{#subobject:d0nx60|Regimen=1}}
- 13:54, 4 March 2024 diff hist +1,028 m Gastric cancer - null regimens →Placebo current
- 13:53, 4 March 2024 diff hist +1,833 m Gastric cancer - historical →Fluorouracil & RT {{#subobject:52e768|Regimen=1}}
- 13:50, 4 March 2024 diff hist -1,649 m Gastric cancer →Metastatic or locally advanced disease, subsequent lines of therapy
- 13:25, 4 March 2024 diff hist +42 m Mitapivat (Pyrukynd)
- 13:24, 4 March 2024 diff hist +42 N Category:Pyruvate kinase deficiency regimens Created page with "Category:Classical hematology regimens" current
- 13:24, 4 March 2024 diff hist +49 m Pyruvate kinase deficiency
- 13:23, 4 March 2024 diff hist +45 N Category:Pyruvate kinase deficiency medications Created page with "Category:Classical hematology medications" current
- 13:23, 4 March 2024 diff hist +74 m Mitapivat (Pyrukynd)
- 13:22, 4 March 2024 diff hist +659 N Pyruvate kinase deficiency Created page with "<span id="BackToTop"></span> <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px;..."
- 13:18, 4 March 2024 diff hist +3,876 m Multiple myeloma, relapsed-refractory
- 13:15, 4 March 2024 diff hist +1,450 m Melanoma - null regimens →Placebo
- 00:15, 4 March 2024 diff hist -8 m Bortezomib (Velcade) →Multiple myeloma current
- 00:12, 4 March 2024 diff hist -3 m Fulvestrant (Faslodex) →History of changes in FDA indication current
- 00:06, 4 March 2024 diff hist +6 m Non-small cell lung cancer, EGFR-mutated
- 00:06, 4 March 2024 diff hist +626 m Amivantamab (Rybrevant) current
- 16:34, 3 March 2024 diff hist +343 m Graft versus host disease →ESBMT
- 16:30, 3 March 2024 diff hist +827 m Prostate cancer
- 16:18, 3 March 2024 diff hist +1,650 m Follicular lymphoma
- 16:15, 3 March 2024 diff hist +111 m Low-grade glioma, pediatric →References
- 16:06, 3 March 2024 diff hist +286 m Teclistamab (Tecvayli) current
- 15:46, 3 March 2024 diff hist +492 m Breast cancer, HER2-positive
- 15:44, 3 March 2024 diff hist +83 m Professional organizations
- 15:43, 3 March 2024 diff hist +278 m Ovarian cancer →ESMO/ESGO
- 13:07, 3 March 2024 diff hist -60 m CNS leukemia current
- 12:51, 3 March 2024 diff hist -59 m CNS leukemia →IT Cytarabine & Methotrexate {{#subobject:7536ce|Regimen=1}}
- 14:12, 2 March 2024 diff hist +118 m Chronic lymphocytic leukemia
- 14:09, 2 March 2024 diff hist +271 m Prostate cancer
- 14:03, 2 March 2024 diff hist +96 m Venous thromboembolism
- 14:02, 2 March 2024 diff hist +71 m Melanoma
- 14:00, 2 March 2024 diff hist +123 m Hepatocellular carcinoma
- 13:58, 2 March 2024 diff hist -107 m Systemic mastocytosis - null regimens current
- 13:58, 2 March 2024 diff hist +29 m Systemic mastocytosis →References
- 13:57, 2 March 2024 diff hist +130 m Cholangiocarcinoma
- 13:56, 2 March 2024 diff hist -38 m Systemic mastocytosis - null regimens
- 13:55, 2 March 2024 diff hist +13 m Systemic mastocytosis
- 13:55, 2 March 2024 diff hist +51 m Systemic mastocytosis - null regimens
- 13:52, 2 March 2024 diff hist +102 m Ovarian cancer
- 13:48, 2 March 2024 diff hist +80 m Melanoma →Pembrolizumab monotherapy {{#subobject:0a3e71|Regimen=1}}
- 13:48, 2 March 2024 diff hist +80 m Melanoma - null regimens →References
- 13:24, 2 March 2024 diff hist +1,044 m Bladder cancer
- 22:00, 1 March 2024 diff hist +219 m Breast cancer →ESMO/ESO
- 21:56, 1 March 2024 diff hist +607 m Breast cancer, BRCA-mutated →Carboplatin & Paclitaxel (CP) {{#subobject:842252|Regimen=1}}
- 17:40, 1 March 2024 diff hist +98 m External links →Guidelines & drug information current
- 17:38, 1 March 2024 diff hist -2 m Waldenström macroglobulinemia
- 12:26, 1 March 2024 diff hist +42 m Peripheral T-cell lymphoma
- 12:26, 1 March 2024 diff hist +42 m Diffuse large B-cell lymphoma
- 12:26, 1 March 2024 diff hist +42 m Mediastinal gray-zone lymphoma current
- 12:09, 1 March 2024 diff hist +228 m Follicular lymphoma
- 12:05, 1 March 2024 diff hist +28 m Mantle cell lymphoma
- 12:05, 1 March 2024 diff hist +42 m Mantle cell lymphoma - null regimens current
- 12:04, 1 March 2024 diff hist +30 m Peripheral T-cell lymphoma - historical
- 12:04, 1 March 2024 diff hist +30 m Cutaneous T-cell lymphoma
- 12:04, 1 March 2024 diff hist +15 m Romidepsin (Istodax) current
- 12:03, 1 March 2024 diff hist +26 m Burkitt lymphoma
- 12:03, 1 March 2024 diff hist +32 m Primary mediastinal B-cell lymphoma
- 12:02, 1 March 2024 diff hist +30 m HIV-associated lymphoma
- 12:02, 1 March 2024 diff hist +15 m Anaplastic large cell lymphoma
- 12:02, 1 March 2024 diff hist +15 m Mediastinal gray-zone lymphoma
- 12:01, 1 March 2024 diff hist +28 m Colorectal cancer, HER2-positive
- 11:59, 1 March 2024 diff hist +28 m Mantle cell lymphoma
- 11:59, 1 March 2024 diff hist +32 m Diffuse large B-cell lymphoma
- 11:59, 1 March 2024 diff hist +32 m Transformed lymphoma
- 11:53, 1 March 2024 diff hist +26 m Multiple myeloma, relapsed-refractory
- 11:52, 1 March 2024 diff hist +26 m Light-chain (AL) amyloidosis
- 11:51, 1 March 2024 diff hist +82 m Selpercatinib (Retevmo) current
- 11:51, 1 March 2024 diff hist +36 m Thyroid cancer, RET-positive
- 11:50, 1 March 2024 diff hist +28 m Malignant solid neoplasm, RET-mutated current
- 11:50, 1 March 2024 diff hist +32 m Non-small cell lung cancer, RET-positive
- 11:49, 1 March 2024 diff hist +70 m Colorectal cancer, KRAS-mutated
- 11:48, 1 March 2024 diff hist +16 m Adagrasib (Krazati) current
- 11:48, 1 March 2024 diff hist +32 m Non-small cell lung cancer, KRAS-mutated
- 11:47, 1 March 2024 diff hist +32 m Clear cell renal cell carcinoma
- 11:47, 1 March 2024 diff hist +34 m Non-clear cell renal cell carcinoma
- 02:21, 1 March 2024 diff hist +30 m Anal cancer
- 02:21, 1 March 2024 diff hist +30 m Small cell lung cancer - historical
- 02:20, 1 March 2024 diff hist +44 m Endometrial cancer
- 02:18, 1 March 2024 diff hist +80 m Non-small cell lung cancer
- 02:18, 1 March 2024 diff hist +76 m Melanoma
- 02:17, 1 March 2024 diff hist +19 m Pembrolizumab (Keytruda)
- 02:16, 1 March 2024 diff hist +26 m Polycythemia vera
- 02:15, 1 March 2024 diff hist +60 m Dostarlimab (Jemperli) current
- 02:15, 1 March 2024 diff hist +32 m Malignant solid neoplasm, MSI-H or dMMR current
- 02:15, 1 March 2024 diff hist +44 m Endometrial cancer
- 02:13, 1 March 2024 diff hist +42 m Pancreatic cancer
- 02:13, 1 March 2024 diff hist +33 m Non-small cell lung cancer, KRAS-mutated
- 02:12, 1 March 2024 diff hist +16 m Sotorasib (Lumakras) current
- 02:09, 1 March 2024 diff hist +28 m Gastric cancer
- 02:09, 1 March 2024 diff hist +28 m Esophageal adenocarcinoma
- 02:09, 1 March 2024 diff hist +75 m Small cell lung cancer - historical
- 02:08, 1 March 2024 diff hist +15 m Nivolumab (Opdivo)
- 02:07, 1 March 2024 diff hist +28 m Chronic lymphocytic leukemia
- 02:06, 1 March 2024 diff hist +28 m Pirtobrutinib (Jaypirca) current
- 02:06, 1 March 2024 diff hist +28 m Mantle cell lymphoma
- 02:04, 1 March 2024 diff hist +20 m Non-small cell lung cancer, RET-positive
- 02:03, 1 March 2024 diff hist +26 m Thyroid cancer, RET-positive →Pralsetinib monotherapy {{#subobject:eahg7q|Regimen=1}}
- 02:02, 1 March 2024 diff hist +28 m Pralsetinib (Gavreto)
- 20:11, 29 February 2024 diff hist +243 m Neuroblastoma
- 19:41, 29 February 2024 diff hist +12 m Multiple myeloma - historical →Prednisolone monotherapy {{#subobject:6a5cf5|Regimen=1}}
- 19:40, 29 February 2024 diff hist +5 m Multiple myeloma, consolidation and maintenance →Thalidomide & Prednisolone {{#subobject:6f8a22|Regimen=1}}
- 19:40, 29 February 2024 diff hist +2 m Multiple myeloma, consolidation and maintenance →Thalidomide & Prednisone (TP) {{#subobject:1agdc9|Regimen=1}}
- 19:39, 29 February 2024 diff hist -2 m Multiple myeloma, consolidation and maintenance →Thalidomide & Prednisone (TP) {{#subobject:c74709|Regimen=1}}
- 18:03, 29 February 2024 diff hist +53 m Breast cancer, ER-positive →Regimen {{#subobject:41c2e3|Variant=1}}
- 17:46, 29 February 2024 diff hist +47 m Breast cancer - null regimens →Observation
- 17:37, 29 February 2024 diff hist +24 m Non-small cell lung cancer, EGFR-mutated
- 18:26, 28 February 2024 diff hist +2 m Melanoma →Lifileucel & IL-2 {{#subobject:f33e1b|Regimen=1}}
- 18:25, 28 February 2024 diff hist -170 m Stub →CapeOx & Pembrolizumab current
- 18:25, 28 February 2024 diff hist +1 m Gastric cancer →CapeOx & Pembrolizumab {{#subobject:1yhy28|Regimen=1}}
- 14:35, 28 February 2024 diff hist +38 m Factor VIIa, recombinant (NovoSeven RT) current
- 14:35, 28 February 2024 diff hist +38 m Factor IX, recombinant current
- 14:35, 28 February 2024 diff hist +38 m Factor VIII, recombinant current
- 14:34, 28 February 2024 diff hist +63 m Therapeutic equivalents →Recombinant proteins current
- 14:34, 28 February 2024 diff hist +38 m Lipefilgrastim (Lonquex) current
- 14:33, 28 February 2024 diff hist +37 m Palifermin (Kepivance) current
- 14:33, 28 February 2024 diff hist +69 m Anakinra (Kineret) current
- 14:33, 28 February 2024 diff hist +38 m BL22 immunotoxin (CAT-3888) current
- 14:32, 28 February 2024 diff hist +18 N Category:Medications by manufacturing method Created page with "Category:Drugs" current
- 14:32, 28 February 2024 diff hist +48 N Category:Recombinant medications Created page with "Category:Medications by manufacturing method" current
- 14:32, 28 February 2024 diff hist +38 m Andexanet alfa (Andexxa) current
- 14:32, 28 February 2024 diff hist +37 m Pentraxin 2 (PRM-151) current
- 14:27, 28 February 2024 diff hist +45 N Category:Profibrinolytics Created page with "Category:Classical hematology medications" current
- 14:06, 28 February 2024 diff hist +45 N Category:Hemoglobin S polymerization inhibitors Created page with "Category:Classical hematology medications" current
- 12:10, 28 February 2024 diff hist +10 m Peripheral T-cell lymphoma →Darinaparsin monotherapy {{#subobject:2cgcb4|Regimen=1}}
- 12:08, 28 February 2024 diff hist +19 m Breast cancer - historical →CVAP (Prednisolone) {{#subobject:4ap43c|Regimen=1}}
- 11:17, 28 February 2024 diff hist 0 m Thyroid cancer, medullary
- 11:16, 28 February 2024 diff hist 0 m Thyroid cancer, medullary →Vandetinib monotherapy {{#subobject:cij5cc|Regimen=1}}
- 19:09, 27 February 2024 diff hist -9 m Clear cell renal cell carcinoma
- 19:07, 27 February 2024 diff hist +1 m Clear cell renal cell carcinoma →References
- 19:04, 27 February 2024 diff hist +96 m Non-small cell lung cancer
- 19:03, 27 February 2024 diff hist +75 m Small cell lung cancer
- 15:51, 26 February 2024 diff hist 0 m Non-small cell lung cancer, EGFR-mutated
- 15:48, 26 February 2024 diff hist -179 m Stub →Cisplatin, Osimertinib, Pemetrexed
- 15:48, 26 February 2024 diff hist -185 m Stub →Carboplatin, Osimertinib, Pemetrexed
- 13:08, 24 February 2024 diff hist +78 N Category:Antineoplastic bispecific antibodies Created page with "Category:Targeted therapeutic Category:Bispecific antibody medications" current
- 13:07, 24 February 2024 diff hist +5 m Category:Anti-EGFR-HGFR bispecific antibodies current
- 13:06, 24 February 2024 diff hist +31 m Category:Immunostimulatory bispecific antibodies current
- 13:05, 24 February 2024 diff hist +44 N Category:Hematologic bispecific antibodies Created page with "Category:Bispecific antibody medications" current
- 13:05, 24 February 2024 diff hist +2 m Category:Anti-Factor IXa-Factor Xa bispecific antibodies current
- 13:04, 24 February 2024 diff hist +44 N Category:Immunostimulatory bispecific antibodies Created page with "Category:Bispecific antibody medications"
- 13:04, 24 February 2024 diff hist +8 m Category:Anti-GPRC5D-CD3 bispecific antibodies current
- 13:04, 24 February 2024 diff hist +8 m Category:Anti-EpCAM-CD3 bispecific antibodies current
- 13:03, 24 February 2024 diff hist +8 m Category:Anti-DLL3-CD3 bispecific antibodies current
- 13:03, 24 February 2024 diff hist +8 m Category:Anti-CD33-CD3 bispecific antibodies current
- 13:03, 24 February 2024 diff hist +8 m Category:Anti-CD20-CD3 bispecific antibodies current
- 13:03, 24 February 2024 diff hist +8 m Category:Anti-CD19-CD3 bispecific antibodies current
- 13:02, 24 February 2024 diff hist +8 m Category:Anti-BCMA-CD3 bispecific antibodies current
- 12:49, 24 February 2024 diff hist -2 m Category:Fluoropyrimidines current
- 08:05, 24 February 2024 diff hist 0 m Melphalan flufenamide (Pepaxto)
- 22:39, 22 February 2024 diff hist +46 m Chronic lymphocytic leukemia
- 22:18, 21 February 2024 diff hist +2 m CNS lymphoma
- 22:14, 21 February 2024 diff hist +1 m Breast cancer, HER2-positive
- 22:13, 21 February 2024 diff hist +1 m Gastric cancer, HER2-positive
- 22:12, 21 February 2024 diff hist +5 m Classical Hodgkin lymphoma
- 22:10, 21 February 2024 diff hist 0 m Breast cancer
- 22:09, 21 February 2024 diff hist +1 m Prostate cancer →References
- 22:08, 21 February 2024 diff hist +1 m Prostate cancer →References
- 21:17, 21 February 2024 diff hist +23 m Follicular lymphoma
- 21:16, 21 February 2024 diff hist +23 m Follicular lymphoma - historical
- 21:16, 21 February 2024 diff hist -24 m Rituximab (Rituxan) current
- 21:37, 19 February 2024 diff hist +57 m Drug index →L
- 21:36, 19 February 2024 diff hist +320 m Lifileuecel (Contego)
- 18:22, 19 February 2024 diff hist +276 m Osimertinib (Tagrisso) →History of changes in FDA indication current
- 18:21, 19 February 2024 diff hist +6 m Non-small cell lung cancer, EGFR-mutated
- 02:26, 19 February 2024 diff hist -14 m Breast cancer, HER2-positive
- 13:05, 18 February 2024 diff hist +5 m Gallbladder cancer
- 18:54, 17 February 2024 diff hist +20 m Complex multipart regimens →Comparative efficacy
- 19:08, 16 February 2024 diff hist +297 m Tepotinib (Tepmetko) →History of changes in FDA indication current
- 18:06, 16 February 2024 diff hist -259 m Non-small cell lung cancer
- 15:47, 16 February 2024 diff hist +689 m Breast cancer, ER-positive →Anastrozole monotherapy {{#subobject:a052f4|Regimen=1}}
- 02:33, 16 February 2024 diff hist +2,211 m Clear cell renal cell carcinoma - null regimens →Placebo
- 02:30, 16 February 2024 diff hist -2,880 m Renal cell carcinoma - null regimens →Metastatic disease, second-line
- 22:55, 15 February 2024 diff hist +20 m Osteosarcoma - historical →References
- 22:48, 15 February 2024 diff hist 0 m Rhabdomyosarcoma, pediatric - historical
- 19:57, 13 February 2024 diff hist +3 m Pancreatic cancer
- 19:56, 13 February 2024 diff hist +109 m Irinotecan liposome (Onivyde) →History of changes in FDA indication current
- 15:33, 12 February 2024 diff hist +15 m Editing test page →Radiotherapy
- 14:21, 12 February 2024 diff hist +22 m Editing test page
- 14:21, 12 February 2024 diff hist +22 m Editing test page
- 14:20, 12 February 2024 diff hist +12 m Editing test page
- 14:20, 12 February 2024 diff hist +62 m Editing test page
- 14:19, 12 February 2024 diff hist +23 m Editing test page
- 14:19, 12 February 2024 diff hist +23 m Editing test page
- 01:42, 12 February 2024 diff hist +719 m Ovarian cancer - null regimens →References
- 01:41, 12 February 2024 diff hist +75 m Ovarian cancer - null regimens →References
- 01:37, 12 February 2024 diff hist +1 m Immune thrombocytopenia
- 00:51, 12 February 2024 diff hist +1 m Melanoma, BRAF-mutated
- 00:36, 12 February 2024 diff hist +6 m Anaplastic glioma
- 00:36, 12 February 2024 diff hist +6 m Glioblastoma
- 00:33, 12 February 2024 diff hist +36 m Breast cancer, HER2-positive
- 00:30, 12 February 2024 diff hist -11 m Prostate cancer →References
- 02:38, 11 February 2024 diff hist -50 m Ovarian cancer
- 14:13, 10 February 2024 diff hist -20 m Head and neck cancer - historical →Radiation therapy {{#subobject:5ac377|Regimen=1}}
- 14:12, 10 February 2024 diff hist -19 m Head and neck cancer →Fluorouracil & RT {{#subobject:3a644e|Regimen=1}}
- 03:28, 10 February 2024 diff hist +9 m Endometrial cancer
- 03:28, 10 February 2024 diff hist +9 m Cholangiocarcinoma
- 03:28, 10 February 2024 diff hist +9 m Malignant solid neoplasm, MSI-H or dMMR
- 03:27, 10 February 2024 diff hist +10 m Colorectal cancer, MSI-H or dMMR →Regimen variant #2, weight-based {{#subobject:B34AD4|Variant=1}}
- 03:12, 10 February 2024 diff hist +101 m Breast cancer, ER-positive →Regimen variant #7, 5 years {{#subobject:dc8bc3|Variant=1}}
- 03:10, 10 February 2024 diff hist +464 m Breast cancer, ER-positive →References
- 03:09, 10 February 2024 diff hist +675 m Breast cancer, ER-positive